Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry. 3. Februar 2023 Metzenmacher M, Griesinger F, Hummel HD, Elender C, Schäfer H, de Wit M, Kaiser U, Kern J, Jänicke M, Spring L, Zacharias S, Kaiser-Osterhues A, Groth A, Hipper A, Zaun G, Dörfel S, Güldenzoph B, Müller L, Uhlig J, Thomas M, Sebastian M, Eberhardt WEE; CRISP Registry Group. Eur Respir J. 2023 Feb 2;61(2):2201336. doi: 10.1183/13993003.01336-2022. Link Checkpoint inhibitor monotherapy in potentially studyeligible or non-study-eligible NSCLC patients in the German CRISP Registry real-world cohort (AIO-TRK-0315). F Griesinger; M Sebastian; W Brückl; H-D Hummel; B Jaeschke; J Kern; C Wesseler; M Jänicke; A Fleitz; S Zacharias; A Hipper; A Groth; W… Weiterlesen FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world Marschner N, Hegewisch-Becker S, Reiser M, von der Heyde E, Bertram M, Hollerbach SH, Kreher S, Wolf T, Binninger A, Chiabudini M, Kaiser-Osterhues A, Jänicke… Weiterlesen